



Statement of Withdrawn Study

Study with EudraCT No.: **2020-002192-35** entitled '*A randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of BAY 2327949 in patients with chronic kidney disease (eGFR range from 25 to 60 mL/min/1.73 m²) due to type 2 diabetes or hypertension and at least one cardiovascular comorbidity*' was registered in the EudraCT database but never started.

Consequently, no results are available for this study.

Bayer AG